Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2005

View Archived Issues

Janex-1 reduces tumorigenesis and improves survival in a mouse model of FAP

New phase II data on the efficacy of 3-AP plus gemcitabine in pancreatic cancer

February meeting of European Committee for Orphan Medicinal Products

Aceon sNDA accepted for filing with priority review

Positive data from phase IIa BrachySil study

Evotec to provide process validation for AMD-3100

Entelos and Organon to extend rheumatoid arthritis collaboration

New collaboration to conduct whole genome association study on breast cancer

Galenea and Otsuka team up for CNS drug discovery efforts

Milestone in Cellular Genomics kinase discovery program with Serono

WinRho SDF shows promise for dengue hemorrhagic fever

OctoPlus and Biolex to jointly develop controlled-release alfa interferon

Enrollment completed in phase II HCV study of Albuferon

Endpoints met in phase III study of indiplon MR for chronic insomnia

Dutch approval for Draxis' diagnostic radiopharmaceutical

FDA reveals safety reviews of etoricoxib, lumiracoxib and parecoxib

Supportive care reported to improve the safety profile of nolatrexed in HCC patients

Clinical evidence on cardiovascular risk with COX-2 inhibitors / News in Context

A subcutaneous histrelin implant shows promise in the treatment of CPP

Excessive scarring prevented by 4-hydroxy tamoxifen (4-OHT)

Transnasal micro-emulsions of diazepam claimed by SK Corporation scientists

Novel factor Xa (FXa) inhibitors discovered at Merck KGaA

Neurogen researchers develop new GABA-A receptor modulators

Two series of beta-2 adrenoreceptor agonists prepared and tested at Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...